Adverum Biotechnologies to Participate in TD Cowen's Genetic Medicines & RNA Summit
Adverum Biotechnologies to Participate in TD Cowen's Genetic Medicines & RNA Summit
REDWOOD CITY, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies, will participate in a fireside chat at TD Cowen's Genetic Medicines & RNA Summit on Friday, June 21, 2024 at 10:00 a.m. ET.
加州雷德伍德城，2024年6月18日（環球新聞社）——生物技術公司Adverum Biotechnologies，Inc. （納斯達克：ADVM）是一家臨床級別的公司，致力於開創基因療法作爲高普及性眼疾的新標準，今天宣佈，Adverum Biotechnologies的總裁兼首席執行官勞倫特·費舍爾醫學博士將參加TD Cowen遺傳藥物和RNA峯會的爐邊聊天，時間是2024年6月21日（星期五）美國東部時間上午10:00。
The webcast of the presentation may be accessed under Events and Presentations in the Investors section of Adverum's website. A replay of the webcast will be available on the website for at least 30 days following the presentation.
在Adverum網站上的投資者部分的活動和演示下可以訪問此次演示的網絡廣播。演示的網絡廣播的重播將在演示後的至少30天內在網站上提供。
About Adverum Biotechnologies
Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the capabilities of its proprietary intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians' offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. Additionally, by overcoming the challenges associated with current treatment paradigms for debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe. For more information, please visit .
關於Adverum生物技術公司
Adverum Biotechnologies（NASDAQ：ADVM）是一家臨床級別的公司，旨在通過開發功能性治癒以恢復視力和預防失明，將基因療法確立爲高普及性眼疾的新標準。利用其專有的玻切（IVT）平台的能力，Adverum正在開發耐久、單次治療，並旨在在臨床醫生辦公室中進行投放的治療方法，以消除治療這些疾病的需要頻繁眼部注射。Adverum正在評估其新型基因療法候選藥物ixoberogene soroparvovec（Ixo-vec，曾用名ADVM-022），作爲一種針對新生血管型或潮溼型年齡相關性黃斑變性的單次IVT注射。此外，通過克服當前治療範式所面臨的挑戰，Adverum的願景是改變治療標準，保護視力，並在全球範圍內產生深遠的社會影響。如需更多信息，請訪問Adverum投資者關係。.
Inquiries:
Adverum Investor Relations
Email: ir@adverum.com
諮詢：
Adverum投資者關係
電子郵件: ir@adverum.com
譯文內容由第三人軟體翻譯。